Drug Profile
Research programme: Src kinase inhibitors - Athenex
Alternative Names: KX-2377Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Kinex Pharmaceuticals
- Developer Athenex
- Class Small molecules
- Mechanism of Action Src-Family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Sensorineural hearing loss
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Sensorineural hearing loss in USA
- 23 Jul 2007 US FDA approves IND application for KX2 391 in patients with solid tumours or lymphoma
- 25 Jun 2007 Kinex Pharmaceuticals files an IND with the US FDA for a phase I trial of KX2 391 in patients with solid tumours or lymphoma